Malignant tumor of breast (disorder)
CiPHER - Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases
Year Started: 2014
Clinical Trial samples from the CiPHER study. Samples include blood (processed to serum and plasma), urine and tissue (FFPE blocks of primary breast tumour, metastatic brain tumour and secondary cranial tissue).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| There is no associated data for this collection. | |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | N/A | Not applicable | 26 - 50% | |
| Serum | -60°C to -85°C | N/A | Not applicable | 26 - 50% | |
| Urine | -60°C to -85°C | N/A | Not applicable | 26 - 50% |
Female
Young adult (18 - 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | N/A | Not applicable | 26 - 50% | |
| Serum | -60°C to -85°C | N/A | Not applicable | 26 - 50% | |
| Urine | -60°C to -85°C | N/A | Not applicable | 26 - 50% |
Malignant melanoma of eye (disorder)
SUAVE - A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma
Year Started: 2010
Clinical trial samples from the SUAVE study. Samples include bloods (serum, plasma and cell pellet).
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| There is no associated data for this collection. | |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | N/A | Not applicable | 26 - 50% | |
| Serum | -60°C to -85°C | N/A | Not applicable | 26 - 50% |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | N/A | Not applicable | 26 - 50% | |
| Serum | -60°C to -85°C | N/A | Not applicable | 26 - 50% |